March 10th 2023
Findings from the patient-reported outcomes analysis of the phase 3 KEYNOTE-826 trial support the benefit of pembrolizumab in patients with recurrent, persistent, or metastatic cervical cancer.
Salani Reviews Role of PARP Inhibition in Ovarian CancerNovember 24th 2022
During a Targeted Oncology case-based roundtable event, Ritu Salani, MD, MBA, discussed multiple studies that back up the use of PARP inhibition as a first-line maintenance therapy for patients with advanced ovarian cancer.
FDA Approves Mirvetuximab Soravtansine in FRα-High Platinum-Resistant Ovarian CancerNovember 14th 2022
Mirvetuximab soravtansine has been granted FDA accelerated approval for use in patients with folate receptor alpha-high platinum-resistant ovarian cancer who have received prior treatment with 1 to 3 prior systemic therapies.
Further Results from SOLO2 Underscore Need for New Strategies to Treat BRCA1/2+ Recurrent Epithelial Ovarian CancerOctober 27th 2022
Additional findings fro the phase 2 SOLO2 study shows that there is a need for research to determine the optimal strategy for patients who relapse after treatment with a PARP inhibitor.
The Role of Rucaparib in Ovarian Cancer Following the ARIEL4 ReadoutOctober 22nd 2022
In an interview with Targeted Oncology™, Amit M. Oza, MD, discussed the overall survival analysis of the ARIEL4 clinical trial and unanswered questions about rucaparib treatment in certain ovarian cancer subgroups.
The Role of Biomarker Testing in Ovarian CancerOctober 17th 2022
There is no single best treatment algorithm for ovarian cancer. Treatment decisions, which become increasingly complex with disease progression, are informed by several patient-specific clinicopathologic parameters and genomic results.
OnPrime Study of Olvi-Vec, Platinum-Doublet, and Bevacizumab Initiates in Ovarian CancerSeptember 26th 2022
Based on preclinical studies which have shown the clinical benefit of Olvi-Vec, a phase 3 trial evaluating the agent in combination with platinum-doublet chemotherapy and bevacizumab has commenced in patients with platinum-resistant/refractory ovarian cancer.
Long-Term Follow-Up Confirms Survival Benefit from Second-Line Cemiplimab for Recurrent/Metastatic Cervical CancerSeptember 11th 2022
With 30 months additional follow-up on the EMPOWER-Cervical 1 trial, cemiplimab monotherapy showed efficacy in patients with metastatic cervical cancer.
Weekly Dose-Dense Paclitaxel Not Recommended as Standard Therapy for 1L Ovarian CancerJuly 29th 2022
Mature survival data from the phase 3 ICON8 trial revealed no significant difference between administering weekly dose-dense chemotherapy and standard 3-weekly chemotherapy as front-line therapy for patients with epithelial ovarian cancer.
Key Takeaways from the OUTBACK Trial of Adjuvant Chemotherapy in Cervical CancerJuly 23rd 2022
Bradley Monk, MD, FACCOG, FACS, discusses main takeaways from the OUTBACK trial of adjuvant chemotherapy following chemoradiation as primary treatment in patients with locally advanced cervical cancer vs chemoradiation alone.
Ofra-vec/Paclitaxel Shows No Significant Survival Benefit in Platinum-Resistant Ovarian CancerJuly 20th 2022
The phase 3 OVAL clinical trial has been discontinued after the combination of ofranergene obadenovec and paclitaxel did not achieve the study’s primary end points of improvement in progression-free and overall survival.
Intermittent Relacorilant With Nab-Paclitaxel Leads to OS Benefit in Pretreated Ovarian Cancer PopulationJuly 13th 2022
Treatment with relacorilant showed improvement in overall survival in patients platinum-resistant or platinum-refractory ovarian cancer when combined with nab-paclitaxel.
Dostarlimab Shows Durable Antitumor Activity in GARNET Trial Expansion Cohorts With Advanced, Recurrent Endometrial CancerJune 8th 2022
Dostarlimab monotherapy induced durable antitumor activity in advanced or recurrent endometrial cancer among patients with mismatch repair deficient/microsatellite instability–high or mismatch repair proficient/mismatch stable disease, according to data from 2 expansion cohorts in the GARNET trial.
Adding Pembrolizumab Extends OS and PFS in Key Subgroups in Recurrent, Metastatic Cervical CancerJune 6th 2022
Results from the KEYNOTE-826 trial showed that chemotherapy plus pembrolizumab with or without bevacizumab improved overall survival and progrssion-free survival in patients with metastatic cervical cancer based on subgroups including histology and prior treatment type.
Lenvatinib/Pembrolizumab Combo Improves Efficacy of Next Line of Therapy in Advanced Endometrial CancerJune 5th 2022
An exploratory analysis of the phase 3 Study 309/KEYNOTE-775 trial evaluating the efficacy of next line of therapy showed clinically meaningful improvements in second progression-free survival and duration of the next line of therapy in patients with previously treated advanced endometrial cancer who received lenvatinib and pembrolizumab vs physician’s choice of chemotherapy.
Adjuvant Immunotherapy Combinations Are Explored in Endometrial CancerMay 20th 2022
The benefit of pembrolizumab compared with placebo in combination with adjuvant chemotherapy with or without radiation therapy in patients with newly diagnosed high-risk endometrial cancer after surgery with curative intent is under evaluation in the ENGOT-en11/GOG-3053/KEYNOTE-B21 trial.
FDA Grants Fast Tracks SQZ-PBMC-HPV for HPV16+ Advanced/Metastatic Solid TumorsApril 28th 2022
The FDA has granted fast track designation to SQZ-PBMC-HPV for the treatment of patient with HPV16-positive advanced or metastatic solids tumors, according to an announcement by SQZ Biotechnologies.
Early Signs of Clinical Promise Noted for Neoadjuvant Chemoimmunotherapy in Advanced Ovarian CancerApril 13th 2022
Eighty-percent of all patients treated with durvalumab and tremelimumab in combination with neoadjuvant chemotherapy at least had a partial response to treatment prior to the end of a phase 2 trial.
NEBULA Trial Looks to Overcome Immunosuppressive TME in Epithelial TumorsApril 12th 2022
The phase 1a/b NEBULA trial is investigating the safety and preliminary efficacy of the adenoviral vector NG-641 in combination with nivolumab in patients with previously treated metastatic or advanced epithelial tumors.
Elimusertib Elicits Response in Patients With Solid Tumors and ATM/BRCA1/2 DefectsApril 11th 2022
According to new data, different dosing strategies of elimusertib for advanced solid tumors with ATM alterations and other DNA damage repair gene defects has demonstrated early efficacy.
Intermittent Relacorilant With Nab-Paclitaxel Extends Survival in Recurrent, Platinum-Resistant Ovarian CancerApril 1st 2022
A survival benefit has been shown in a phase 2 study using intermittent relacorilant and nab-paclitaxel for the treatment of patients with recurrent, platinum-resistant ovarian cancer.
Rucaparib Demonstrates PFS Benefit in Newly Diagnosed Ovarian Cancer With or Without Positive HRDMarch 31st 2022
The phase 3 ATHENA-MONO trial meet it primary end point of improvement in progression-free survival with rucaparib in patients with newly-diagnosed, advanced ovarian cancer.